Landmark 2026 Breakthrough: Experimental Pancreatic Cancer Drug Doubles Survival Rates in Historic Clinical Trial
A landmark 2026 Phase 3 clinical trial reveals that an experimental stroma-modulating immunotherapy has successfully dou...
Read More →Health and wellness news.
A landmark 2026 Phase 3 clinical trial reveals that an experimental stroma-modulating immunotherapy has successfully dou...
Read More →The FDA has approved Xocova (ensitrelvir) as the first oral antiviral for post-exposure COVID-19 prevention, offering a ...
Read More →The WHO has endorsed CRISPR-enhanced bacteriophage therapy as a first-line treatment for carbapenem-resistant infections...
Read More →Altos Labs reports the first human clinical data showing that transient, partial epigenetic reprogramming using OSKM mRN...
Read More →Duke University researchers demonstrate that targeted lipid nanoparticles can cross the blood-brain barrier to deliver s...
Read More →MIT engineers have developed a wearable aptamer-based biosensor for continuous, non-invasive monitoring of cortisol in i...
Read More →The FDA has approved MDMA-assisted psychotherapy for severe PTSD based on Phase 3 MAPS trial data. The treatment combine...
Read More →A Phase 2 trial at MD Anderson demonstrates that the senolytic combination dasatinib and quercetin (D+Q) significantly s...
Read More →UCSD researchers validate an AI-driven liquid biopsy platform that detects early-stage pancreatic cancer via cfDNA methy...
Read More →Mayo Clinic researchers identify gut microbiome-derived metabolites, specifically LPS and depleted SCFAs, as primary dri...
Read More →